Achillion Pharma (ACHN) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Data Could Lead to Achillion Pharmaceuticals (ACHN) Takeover By Year End - Analyst
March 6, 2015 1:32 PM ESTWilliam Blair analyst Y. Katherine Xu offered some interesting commentary on Achillion Pharmaceuticals (NASDAQ: ACHN) after the company's "uneventful" fourth quarter report. While keeping her Market Perform rating and lowering her price target to $14.00 (from $15.00), Xu highlighted that Achillion intends to initiate three different combination studies in the treatment of hepatitis C virus (HCV) during 2015 to... More
